论文部分内容阅读
目的探讨肝癌组织PIK3CA基因突变状况对肝癌手术切除治疗效果及其预后的影响。方法采用PCR及DNA序列测定法检测79例肝癌组织中的PIK3CA基因突变情况,并分析其对肝癌患者近期以及远期疗效的影响。结果本组79例患者中PIK3CA基因第9外显子突变率为39.24%(31/79);PIK3CA基因第9外显子突变率与淋巴结转移及肿瘤分化的程度有关(P<0.05);突变组患者的近期治疗效果明显差于未突变组(P<0.05);Kaplan-Meier生存分析结果显示,突变组患者术后3年累积生存率(33.33%)明显低于未突变组(60.00%),P<0.05。结论 PIK3CA基因第9外显子突变可降低肝癌患者手术切除的治愈率和有效率,并对较差的生存预后具有提示作用。
Objective To investigate the effect of PIK3CA gene mutation in hepatocellular carcinoma on surgical resection and prognosis of hepatocellular carcinoma. Methods The mutation of PIK3CA gene in 79 cases of hepatocellular carcinoma was detected by PCR and DNA sequencing. The effect of PIK3CA gene on the short-term and long-term efficacy of hepatocellular carcinoma was analyzed. Results The mutation rate of exon 9 in PIK3CA gene was 39.24% (31/79) in 79 patients. The mutation rate of exon 9 in PIK3CA gene was correlated with the degree of lymph node metastasis and tumor differentiation (P <0.05). The mutation (P <0.05). The Kaplan-Meier survival analysis showed that the 3-year cumulative survival rate (33.33%) of the patients in the mutation group was significantly lower than that of the non-mutation group (60.00%) , P <0.05. Conclusion The mutation of exon 9 of PIK3CA gene can reduce the cure rate and efficiency of surgical resection in patients with liver cancer, and may be a hint for poor survival prognosis.